The combination of nivolumab and ipilimumab improved overall survival (OS) over sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC), according to results of the CheckMate 214 trial presented at the ESMO 2017 Congress (abstract LBA 5).
The phase 3, randomized, open-label trial was stopped early after it met one of its primary end points: improved OS with nivolumab (Opdivo, Bristol-Myers Squibb) and ipilimumab (Yervoy, Bristol-Myers Squibb) compared